Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Bradbury also recently made the following trade(s):

• On Monday, January 6th, Daniel Bradbury sold 7,867 shares of Castle Biosciences stock. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38.

Castle Biosciences Stock Performance

CSTL opened at $27.60 on Monday. The business’s 50-day simple moving average is $28.20 and its 200 day simple moving average is $28.91. Castle Biosciences, Inc. has a 52-week low of $16.97 and a 52-week high of $35.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The firm has a market capitalization of $773.08 million, a PE ratio of 138.01 and a beta of 0.91.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. R Squared Ltd bought a new position in shares of Castle Biosciences in the fourth quarter valued at $42,000. Quest Partners LLC grew its holdings in Castle Biosciences by 54.4% during the third quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock worth $123,000 after purchasing an additional 1,522 shares during the period. US Bancorp DE increased its position in Castle Biosciences by 1,889.2% during the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock worth $132,000 after buying an additional 4,383 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Castle Biosciences in the third quarter valued at approximately $140,000. Finally, Assetmark Inc. lifted its position in shares of Castle Biosciences by 16.8% in the third quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after buying an additional 748 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Stephens reaffirmed an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research report on Thursday, January 2nd. BTIG Research boosted their price target on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, October 14th. KeyCorp increased their price objective on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Canaccord Genuity Group boosted their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Finally, Lake Street Capital upped their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $40.29.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.